Statera Biopharma, Inc.(NASDAQ : STAB)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||0.33%||6.28||0.7%||$439.00m|
|REGN||Regeneron Pharmaceuticals, Inc.||2.19%||555.39||2.7%||$428.75m|
|GILD||Gilead Sciences, Inc.||1.24%||66.72||1.0%||$412.91m|
|XLRN||Acceleron Pharma, Inc.||0.25%||173.44||5.3%||$363.37m|
|VRTX||Vertex Pharmaceuticals, Inc.||2.14%||184.67||1.9%||$263.79m|
|XENE||Xenon Pharmaceuticals, Inc.||1.43%||31.16||0.4%||$174.21m|
|CRSP||CRISPR Therapeutics AG||5.11%||101.13||0.6%||$162.10m|
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia. The firm is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohnâ€™s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.